JNJ-87890387 for Cancer

Recruiting at 6 trial locations

Overseen By Study Contact

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Janssen Research & Development, LLC

Must not be taking: Immunotherapy

Disqualifiers: CNS involvement, Transplantation, Bowel obstruction, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

158 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

Do I need to stop my current medications for the trial?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research Team

Janssen Research & Development, LLC Clinical Trial

Principal Investigator

Janssen Research & Development, LLC

Eligibility Criteria

This trial is for individuals with advanced solid tumors. Specific eligibility criteria are not provided, but typically participants must have a measurable disease and be in good general health.

Inclusion Criteria

I am fully active or restricted in physically strenuous activity but can do light work.

My cancer is one of the specified types and cannot be removed by surgery.

My cancer can be measured or evaluated by medical tests.

Exclusion Criteria

I haven't been hospitalized for a bowel blockage in the last 30 days.

My brain metastases are stable, and I've been on low-dose steroids or none for 2 weeks.

My side effects from previous cancer treatments are mild, except for hair loss, skin changes, mild nerve damage, or hormone issues that are under control.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive JNJ-87890387 with dose escalation to determine the recommended phase 2 dose (RP2D)

Up to 21 days

Multiple visits for dose escalation and monitoring

Dose Expansion

Participants receive JNJ-87890387 at the RP2D regimen(s) determined in Part 1

Up to 2 years 9 months

Regular visits for treatment and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• JNJ-87890387

Trial Overview The study is testing the safety and appropriate dosage of a new medication called JNJ-87890387 for treating advanced solid tumors.

Participant Groups

Group I: JNJ-87890387 Experimental Treatment 1 Intervention

In Part 1 (Dose escalation) participants will receive JNJ-87890387. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified. In Part 2 (Dose expansion), participants will receive JNJ-87890387 at the RP2D regimen(s) determined in Part 1.

Who Is Running the Clinical Trial?

Janssen Research & Development, LLC

Lead Sponsor

Trials

1,022

Recruited

6,408,000+

Giacomo Salvadore

Janssen Research & Development, LLC

Chief Medical Officer since 2023

MD from the University of Rome, Tor Vergata

Ricardo Attar

Janssen Research & Development, LLC

Chief Executive Officer since 2008

PhD in Molecular Biology from the University of Buenos Aires